JOURNAL OF CLINICAL LABORATORY ANALYSIS, cilt.31, sa.5, 2017 (SCI-Expanded)
BackgroundLiver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non-invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non-invasive fibrosis marker in chronic hepatitis B patients.